UCBUCBJF +2.01%91 FCF Margin % is 32.02% as of Dec. 2025, which is 124% above its 10-year median of 14.32. GuruFocus rates UCBJF with a GF Score™ of 91/100 and a GF Value™ of $262.49 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, UCB ranks better than 90.93% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. UCB's Free Cash Flow for the
six
months ended in Dec. 2025 was $1,595 Mil. UCB's Revenue for the
six
months ended in Dec. 2025 was $4,981 Mil. Therefore, UCB's FCF Margin % for the quarter that ended in Dec. 2025 was 32.02%.
The historical rank and industry rank for UCB's FCF Margin % or its related term are showing as below:
UCBJF'
s FCF Margin % Range Over the Past 10 Years
Min: 6.97 Med: 14.32 Max: 23.86
Current: 23.86
During the past 13 years, the highest FCF Margin % of UCB was 23.86%. The lowest was 6.97%. And the median was 14.32%.
UCBJF's FCF Margin % is ranked better than 90.93% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs UCBJF: 23.86
UCB FCF Margin % Related Terms
UCB FCF Margin % Historical Data
* Premium members only.
The historical data trend for UCB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCBJF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, UCB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where UCB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (UCBJF) has a FCF Margin % of 32.02% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UCB and its competitors. This is 124% above median its historical median of 14.32. Over the past decade, UCB's FCF Margin % has ranged from 6.97 to 23.86. According to the industry distribution chart, UCB ranks #87 out of 959 companies in the Biotechnology industry, placing it in the top 9.1%.
Is UCB's FCF Margin % too high?
UCB's current FCF Margin % of 32.02% is 124% above median its 10-year median of 14.32. Over the past 10 years, this metric has ranged from a low of 6.97 to a high of 23.86. Based on the distribution chart, UCB ranks #87 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #87 out of 959 companies for FCF Margin %. This places UCB in the top 9% of its industry — outperforming the majority of peers. Historically, UCB's own FCF Margin % has ranged from 6.97 to 23.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UCB and its competitors. UCB's current FCF Margin % is 32.02%, which is 124% above median its own 10-year median of 14.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (UCBJF) is currently considered Modestly Overvalued. The stock's GF Value™ is $262.49, compared to a current price of $302.69 — trading 15.3% above its estimated fair value. The current FCF Margin % is 32.02%, which is 124% above median its 10-year median of 14.32. UCB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For UCB (UCBJF), the current FCF Margin % is 32.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (UCBJF) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of $302.69 is trading 15.3% above its estimated GF Value™ of $262.49.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for UCBJF:
FCF Margin %: 32.02% (124% above median its 10-year median of 14.32)
GF Value™: $262.49 vs. price of $302.69 (15.3% above fair value)
No single metric tells the full story. See the UCBJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score
Get the complete analysis for UCBJF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UCBJF has been successfully added to your 
